Benzimidazole derivatives

Details Benzimidazole derivatives Benzimidazole derivatives

2005-04-26

2005-04-26

Morris, Patricia L. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S273700

Reexamination Certificate

active

06884810

ABSTRACT:
A benzimidazole derivative of formula (1):(wherein R represents a hydrogen atom or a methoxy group, and n is 0 or 1) or a salt thereof; and a medicament containing the same.The compounds of the present invention, due to minimized difference in therapeutic effect between subjects, which difference would otherwise be derived from different CYP2C19 activity from subject to subject, ensure that all patients can enjoy proper therapeutic effects at the same dose of the drug. Also, the compounds of the invention have low risk of drug interaction caused by induction of CYP1A family member enzymes, as well as low risk of development of cancer, and thus is useful as a remedy for peptic ulcer, reliably providing therapeutic effects with safety.

REFERENCES:
patent: 4255431 (1981-03-01), Junggren et al.
patent: 4508905 (1985-04-01), Junggren et al.
patent: 4628098 (1986-12-01), Nohara et al.
patent: 4689333 (1987-08-01), Nohara et al.
patent: 4738975 (1988-04-01), Nohara et al.
patent: 4758579 (1988-07-01), Kohl et al.
patent: 5013743 (1991-05-01), Iwahi et al.
patent: 5045552 (1991-09-01), Souda et al.
patent: 5223515 (1993-06-01), Mikura et al.
patent: 5840910 (1998-11-01), Souda et al.
patent: 5877192 (1999-03-01), Lindberg et al.
patent: 5998445 (1999-12-01), Souda et al.
patent: 0 208 452 (1987-01-01), None
patent: 268956 (1988-06-01), None
patent: 356143 (1990-02-01), None
patent: 382489 (1990-08-01), None
patent: 54-141783 (1979-11-01), None
patent: 61-022079 (1986-01-01), None
patent: 61-050978 (1986-03-01), None
patent: 62-205077 (1987-09-01), None
patent: 64-006270 (1989-01-01), None
patent: WO 9427988 (1994-12-01), None
T. Ando, et al., Proceedings of the Japanese Society of Gastric Secretion Research, vol. 34, pp. 39-40, “Study on the Treatment of Gastric Ulcer Considering the Characteristics of Genetic Polymorphism of the Metabolic Enzyme CYP2C19”, Aug. 31, 2002 (with English translation).
T. Shimatani, et al., Proceedings of the Japanese Society of Gastric Secretion Research, vol. 34, pp. 99-103, “Are Proton Pump Inhibitors the Most Potent Gastric Acid Secretion Inhibitors?”, Aug. 31, 2002, (with English translation).
J. Kodaira, et al., Proceedings of the Japanese Society of Gastric Secretion Research, vol. 34, pp. 105-108, “Relation Between Acid Secretion Inhibition Effect of PPIS and CYP2C19 Genetic Polymorphisms inH. Pylori-Negative Healthy Volunteers”, Aug. 31, 2002 (with English translation).
H. Saito, et al., Proceedings of the Japanese Society of Gastric Secretion Research, vol. 34, pp. 109-112, “Acid Secretion Inhibition Effect of PPI at an Initial Stage of Administration (in the Case of CYP2C19EM)”, Aug. 31, 2002 (with English translation).
T. Ishizaki, Nikkei Medical, PP12001 No. 7, pp. 174-175, “What do the Latest Findings in Clinical Pharmacology Say About Choosing the Right PPI?”, Feb. 2001 (with English translation).
K. Adachi, et al., Aliment Pharmacol Ther, vol. 14, pp. 1259-1266, “CYP2C19 Genotype Status and Intragastric pH During Dosing with Lansoprazole or Rabeprazole”, 2000.
T. Andersson, Clin. Pharmacokinet., vol. 31, No. 1, pp. 9-28, “Pharmacokinetics, Metabolism and Interactions of Acid Pump Inhibitors”, Jul. 1996.
Y. Horai, et al., Aliment Pharmacol Ther, vol. 15, pp. 793-803, “Pharmacodynamic Effects and Kinetic Disposition of Rabeprazole in Relation to CYP2C19 Genotypes”, 2001.
S. Krusekopf, et al., Xenobiotica, vol. 27, No. 1, pp. 1-9, “Effects of Benzimidazole Derivatives on Cytochrome P450 1A1 Expression in a Human Hepatoma Cell Line”, 1997.
T. Furuta, et al., Annals of Internal Medicine, vol. 129, No. 12, pp. 1027-1030, “Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates forHelicobacter PyloriInfection and Peptic Ulcer”, Dec. 15, 1998.
T. Furuta, et al., Gastroenterology, vol. 120, Supp. 1, #2203, p. A432, “Effects of Genotypic Differences in CYP2C19 Status on the Cure Rates for Gastoesophageal Reflux Disease by Lansoplazole”, 2001.
S.- H. Park, et al., Gastroenterology, vol. 120, Supp. 1, #2219, p. A435, “Effect of CYP2C19 Polymorphism on Rabeprazole Induced Nocturnal Acid Breakthrough”, 2001.
M. Sagar, et al., Aliment Pharmacol Ther, vol. 13, pp. 453-456, “Effect of CYP2C19 Polymorphism on Serum Levels of Vitamin B12in Patients on Long-Term Omeprazole Treatment”, 1999.
T. Kokufu, et al., Eur J Clin Pharmacol, vol. 48, pp. 391-395, “Effects of Lansoprazole on Pharmacokinetics and Metabolism of Theophylline”, 1995.
D. Diaz, et al., Gastroenterology, vol. 99, No. 3, pp. 737-747, “Omeprazole is an Aryl Hydrocarbon-Like Inducer of Human Hepatic Cytochrome P450”, Sep. 1990.
Proceedings of the Japanese Society of Gastric Secretion Research, vol. 34, pp. 39-40, 2002.
Proceedings of the Japanese Society of Gastric Secretion Research, vol. 34, pp. 99-103, 2002.
Proceedings of the Japanese Society of Gastric Secretion Research, vol. 34, pp. 105-108, 2002.
Proceedings of the Japanese Society of Gastric Secretion Research, vol. 34, pp. 109-112, 2002.
Nlkkei Medical, pp. 174-175, Feb. 2001.
K. Adachi, et al., Aliment Pharmacol Ther, vol. 14, pp. 1259-1266, “CYP2C19 Genotype Status and Intragastric PH During Dosing with Lansoprazole or Rabeprazole”, 2000.

Affiliated with

Also associated with

Rating

Benzimidazole derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Benzimidazole derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzimidazole derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3436829